The Institute for Clinical and Economic Review's (ICER) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Biogen's Spinzara therapy if priced at $2m. Dave Lennon, president of Novartis' “I think HCV could have benefitted from that type of approach.” AveXis unit, said ICER's report is positive for cell-based therapies and gene-therapy assessments but highlights the need for bio-pharmaceutical companies to consider offering alternative payment models for such therapies. " The study shows that there are many ways in which we can improve our understanding of how these treatments work - including by looking into other options like payments or insurance coverage," Lennon said.
The Institute for Clinical and Economic Review's (ICER) analysis of experimental gene therapy Zolgensma from Novartis found it would be more cost effective than Biogen's Spinzara therapy if priced at $2m. Dave Lennon, president of Novartis' AveXis unit, said ICER's report is positive for cell-based therapies and gene-therapy assessments but highlights the need for bio-pharmaceutical companies to consider offering alternative payment models for such therapies. "The study shows that there are many ways in which we can improve our understanding of how these treatments work - including by looking into other options like payments or insurance coverage," Lennon said.